SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

November 05, 2015 07:30 ET

Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress

Corporate Update Call at 10:00 am ET Today

BUFFALO, NY--(Marketwired - Nov 5, 2015) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter and nine-month period ended September 30, 2015.

Cleveland BioLabs reported a $3.1 million net loss for the third quarter of 2015, or $0.31 per share, compared to a net loss of $4.1 million, or $1.43 per share, for the same period in 2014. Net loss for the nine-month period was $11.2 million, or $1.93 per share, compared to a net loss of $9.6 million, or $3.64 per share, for the same period in 2014. The improvement in net loss for the third quarter of 2015 was mainly due to the noncash change in the outstanding warrant liability. The increase in loss for the nine -month period was due to the noncash change in the outstanding warrant liability offset by general cost reductions and reduced interest charges related to declining debt balances.

As of September 30, 2015, the Company had $22.5 million in cash, cash equivalents and short-term investments. On July 9, 2015, the Company announced that it sold 6,459,948 unregistered shares of common stock at a price per share of $3.87 for an aggregate of $25.0 million to a venture capital investor. On June 30, 2015, the previously announced option to purchase the Company's remaining interest in Incuron, LLC for $1.0 million was exercised, and payment for such exercise was received in July 2015. Additionally, in August the Company elected to prepay all of the outstanding obligations under its note payable to Hercules Technology Growth Capital which amounted to approximately $2.0 million.

Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, "We have achieved several important milestones during the quarter, including: Significant new funding of $25 million from a strategic investor, and award of $15.8 million from the Department of Defense Congressionally Directed Medical Research Programs. These awards will fund additional studies of entolimod, which are needed for a Biologics License Application. Additionally, we continue to work with the U.S. Food and Drug Administration as they review our pre-Emergency Use Authorization dossier. A positive outcome of this review could enable use of entolimod in an emergency when there are no adequate, approved, and available alternatives, as well as stockpiling by certain US government stakeholders."

Additional Operational Highlights

  • Studies demonstrating the ability of entolimod to reduce radiation injury and improve survival when the drug is administered up to 48 hours after lethal radiation exposure in nonhuman primates were published in the peer-reviewed scientific journal, PLOS One on September 14 (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0135388 or http://www.ncbi.nlm.nih.gov/pubmed/26367124).
  • Enrollment continues in a second Phase 1 study of entolimod in patients with advanced cancer in the Russian Federation to expand upon clinical observations made at higher dose levels in a prior U.S. Phase 1 study and to gather further statistics on immune response to administrations of entolimod. 
  • Preparations to begin a Phase 2 evaluation of CBLB612 in a clinical model of chemotherapy-induced myelosuppression are ongoing in the Russian Federation. Enrollment is expected to begin before the end of 2015.
  • Panacela Labs continues dosing in a Phase 1 study with Mobilan evaluating single injections administered directly into the prostate of patients with prostate cancer. 

All of the studies being conducted in the Russian Federation are supported by development contracts with the Russian Federation Ministry of Industry and Trade, or MPT.

Further Financial Results

Revenue for the third quarter of 2015 increased slightly to $0.5 million compared to $0.4 million for the third quarter of 2014. Revenue for the nine-month period decreased to $1.4 million compared to $2.3 million for the same period last year. This decrease primarily related to the final $1.0 million in revenue from the Skolkovo Foundation, which was recognized in 2014 for Curaxin research associated with Incuron, LLC (which was deconsolidated in the fourth quarter of 2014); with offsetting variances in levels of development work reimbursable under other contracts.

Research and development costs for the third quarter of 2015 were unchanged at $2.1 million compared to the same period in 2014. Research and development costs for the nine-month period decreased to $5.2 million compared to $6.8 million for the same period last year. This decrease was primarily due to the deconsolidation of Incuron, LLC and other variances in the levels of outsourced research.

General and administrative costs for the third quarter of 2015 decreased to $1.3 million compared to $1.8 million for the same period in 2014. General and administrative costs for the nine-month period decreased to $5.2 million compared to $6.4 million for the same period last year. These decreases primarily resulted from the deconsolidation of Incuron, LLC and other reductions in personnel and outside professional costs.

At September 30, 2015 the Company had approximately 10.7 million shares of common stock outstanding. In addition, the Company has 356,735 shares of common stock reserved for issuance pursuant to outstanding stock options with a weighted average exercise price of $47.99 and 2.2 million shares of common stock reserved for issuance pursuant to outstanding warrants exercisable at a weighted average price of $13.98. 

Conference Call Information
Cleveland BioLabs management will host a conference call at 10:00 a.m. ET today to provide updates and address investor questions regarding general business developments. Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs website at www.cbiolabs.com. A replay of the call will be available starting on November 5, 2015, at 1:00 p.m. ET through November 19, 2015, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13622699. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs website at www.cbiolabs.com.

About Cleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. The company's proprietary platform of Toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's most advanced product candidate is entolimod, which is being developed for a biodefense indication and as an immunotherapy for oncology and other indications. The company conducts business in the United States and in the Russian Federation through a wholly-owned subsidiary, BioLab 612, LLC and a joint venture with OJSC Rusnano, Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

This press release contains certain forward-looking information about Cleveland BioLabs that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words and phrases such as "believe," "assuming" "we estimate" "will," "may," "potential," "continue," "proposals," "expected" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to discover and support indications for our therapeutic products; our ability to successfully submit and receive approval of our pre-Emergency Use Application for entolimod; the conduct and results of our various clinical trials; our ability to obtain approval from the U.S. Food and Drug Administration of our product candidates; our ability to conduct studies that are required for a Biologics License Application; potential funding from the Department of Defense and other government agencies; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. 

These risks and uncertainties include, among others, the Company's failure to successfully and timely develop existing and new products; the Company's collaborative relationships and the financial risks related thereto; the risks inherent in the early stages of drug development and in conducting clinical trials; the Company's ability to comply with its obligations under license agreements; the Company's inability to obtain regulatory approval in a timely manner or at all; the unavailability of funds from the Department of Defense and the Company's inability to satisfy conditions related thereto; subsequent changes in the agreement with the Russian Ministry of Industry and Trade; and the Company's history of operating losses and the potential for future losses, which may lead the Company to not be able to continue as a going concern. Some of these factors could cause future results to materially differ from the recent results or those projected in forward-looking statements. See also the "Risk Factors" and "Forward-Looking Statements" described in the Company's periodic filings with the Securities and Exchange Commission.

   
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
         
  September 30,   December 31,  
  2015   2014  
  (Unaudited)      
ASSETS  
Current assets:            
  Cash and cash equivalents $ 6,362,679   $ 3,103,969  
  Short-term investments   16,151,455     -  
  Accounts receivable   366,310     267,199  
  Other current assets   505,594     174,179  
    23,386,038     3,545,347  
             
Equipment, net   151,683     244,537  
Restricted cash   1,097,579     1,699,759  
Other long-term assets   26,681     56,131  
Investment in Incuron, LLC   -     4,268,458  
Total assets $ 24,661,981   $ 9,814,232  
             
LIABILITIES & STOCKHOLDERS' EQUITY  
             
Current liabilities:            
  Accounts payable $ 623,293   $ 1,057,743  
  Accrued expenses   1,822,850     1,804,456  
  Deferred revenue   255,530     156,317  
  Accrued warrant liability   5,309,674     862,074  
  Current portion of note payable   2,125,416     2,640,968  
  Current portion of capital lease obligation   -     7,522  
    10,136,763     6,529,080  
             
Long-term debt   -     1,499,050  
Commitments and contingencies   -     -  
             
  Total liabilities   10,136,763     8,028,130  
             
Stockholders' equity:            
Total Cleveland BioLabs, Inc. stockholders' equity/(deficit)   10,629,096     (1,607,397 )
Noncontrolling interest in stockholders' equity   3,896,122     3,393,499  
  Total stockholders' equity   14,525,218     1,786,102  
Total liabilities and stockholders' equity $ 24,661,981   $ 9,814,232  
             
             
             
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(UNAUDITED)  
                       
  Quarter ended September 30,     Year to Date September 30,  
  2015     2014     2015     2014  
Revenues:              
  Grants and contracts $ 501,555     $ 415,126     $ 1,438,792     $ 2,311,467  
                               
Operating expenses:                              
  Research and development   2,052,567       2,068,245       5,246,706       6,832,241  
  General and administrative   1,266,144       1,785,620       5,171,571       6,449,531  
    Total operating expenses   3,318,711       3,853,865       10,418,277       13,281,772  
                               
Loss from operations   (2,817,156 )     (3,438,739 )     (8,979,485 )     (10,970,305 )
                               
Other income (expense):                              
  Interest and other expense   (233,343 )     (68,932 )     (361,153 )     (1,010,640 )
  Foreign exchange gain (loss)   (212,117 )     (271,699 )     (190,794 )     (330,876 )
  Change in value of warrant liability   46,716       (836,293 )     (1,482,690 )     1,663,390  
  Equity in loss of Incuron, LLC   -       -       (362,137 )     -  
    Total other income (expense)   (398,744 )     (1,176,924 )     (2,396,774 )     321,874  
                               
Net loss   (3,215,900 )     (4,615,663 )     (11,376,259 )     (10,648,431 )
                               
Net loss attributable to noncontrolling interests   95,701       519,529       161,085       1,005,764  
                               
Net loss attributable to Cleveland BioLabs, Inc. $ (3,120,199 )   $ (4,096,134 )   $ (11,215,174 )   $ (9,642,667 )
                               
Net loss per share, basic and diluted $ (0.31 )   $ (1.43 )   $ (1.93 )   $ (3.64 )
                               
Weighted average number of shares, basic and diluted   10,168,342       2,855,510       5,810,293       2,650,808  
                               
                               
   
CLEVELAND BIOLABS, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
(UNAUDITED)  
           
  For the Nine Months Ended September 30,  
  2015     2014  
       
Cash flows used in operating activities $ (8,859,645 )   $ (11,316,565 )
Cash flows used in investing activities   (12,792,474 )     (1,142,661 )
Cash flows provided by financing activities   24,809,045       10,788,298  
Effect of exchange rate change on cash and equivalents   101,784       (500,106 )
               
Increase (decrease) in cash and cash equivalents   3,258,710       (2,171,034 )
               
Cash and cash equivalents at beginning of period   3,103,969       10,048,466  
               
Cash and cash equivalents at end of period $ 6,362,679     $ 7,877,432  
               

Contact Information

  • Contact:
    Rachel Levine
    Vice President, Investor Relations
    Cleveland BioLabs, Inc.
    T: (917) 375-2935
    E: rlevine@cbiolabs.com